Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 25 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding the launch of an innovative Semaglutide Injection in India, coinciding with the patent expiry of the drug. The injection will be marketed under the brand names SEMAGLYN, MASHEMA, and ALTERME, and features a novel drug delivery system that enhances patient convenience and adherence. This initiative aims to address the growing health concerns related to diabetes and obesity in India, which affect a significant portion of the adult population.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases